Improving the Complex Treatment of Experimental Diabetic Purulent-Necrotic Wounds in the Lower Extremities Based on Pathophysiological Indicators

Abstract

Currently, there is no standardized treatment for diabetes and its complications. In treating diabetes mellitus complications, an individualized approach is applied to each patient. For this reason, our locally developed drug Reomannisol has proven effective in treating diabetic purulent-necrotic lesions. Through our biochemical, immunohistochemical, and pathomorphological studies, we have obtained the expected results confirming that the drug is effective in treating purulent-necrotic foot lesions in diabetes mellitus. Changes can be observed in MDA, the cytokine system (IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, TNF-α, INF-γ), and vital organs of the experimentally studied rats, leading to endogenous intoxication. As a complement to our domestic drug, ozone therapy was selected